Mabqi

Scientific publications

Selected publications from Mabqi team and founders

First-in-class anti-TRPV6 antibody as a new therapeutic agent in cancer.

Lindsay B. Alcaraz, Vincent Roux-Portalez, Aurélien Haustrate, Gautier Robin, Alexia Parmentier, Clément Cordier, Florence Boissière-Michot, Amélie Gudin-de-Vallerin, Evelyne Lopez-Crapez, Gaelle Fromont-Hankard, Tristan Mangeat, Margaux Maurel, Marianne Le Gall, Thierry Chardès, Bruno Robert, Yoann Sottejeau, Diego Tosi, Natacha Prevarskaya, V’yacheslav Lehen’kyi, Bernard Pau, Johanna Marines

Cancer Res (2025) 85 (8_Supplement_1): 4770.

https://doi.org/10.1158/1538-7445.AM2025-4770

Targeting RGMb interactions: Discovery and preclinical characterization of potent anti-RGMb antibodies blocking multiple ligand bindings.

Maria Meira, Aurore Frey, Neila Chekkat, Magda Rybczynska, Zaki Sellam, Joon Seok Park, Francesca Smylie Gazzaniga, Alexia Parmentier, Marianne Le Gall, Gordon James Freeman, Dennis Lee Kasper, Arlene Helen Sharpe, Eric Rambeaux, and Abdijapar Shamshiev

mAbs, 2024

https://www.tandfonline.com/doi/full/10.1080/19420862.2024.2432403

Trpv6 channel targeting using monoclonal antibody induces prostate cancer cell apoptosis and tumor regression.

Aurélien Haustrate, Clément Cordier, George Shapovalov, Adriana Mihalache, Emilie Desruelles, Benjamin Soret, Nadège Charlène Essonghé, Corentin Spriet, Maya Yassine, Alexandre Barras, Johanna Marines, Lindsay B Alcaraz, Sabine Szunerits, Gautier Robin, Pierre Gosset, Natalia Prevarskaya, V’yacheslav Lehen’kyi

Cell Death Dis, 2024

https://www.nature.com/articles/s41419-024-06809-0

Antibody-mediated neutralization of galectin-3 as a strategy for the treatment of systemic sclerosis.

Céline Ortega-Ferreira, Perrine Soret, Gautier Robin, Silvia Speca, Sandra Hubert, Marianne Le Gall, Emiko Desvaux, Manel Jendoubi, Julie Saint-Paul, Loubna Chadli , Agnès Chomel , Sylvie Berger , Emmanuel Nony , Béatrice Neau, Benjamin Fould , Anne Licznar, Franck Levasseur, Thomas Guerrier, Sahar Elouej, Sophie Courtade-Gaïani, Nicolas Provost, The Quyen Nguyen , Julien Verdier, David Launay, Frédéric De Ceuninck

Nat Commun, 2023 

https://www.nature.com/articles/s41467-023-41117-9

Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.

Yahya Ashraf, Hanane Mansouri, Valérie Laurent-Matha, Lindsay B Alcaraz, Pascal Roger, Séverine Guiu, Danielle Derocq, Gautier Robin, Henri-Alexandre Michaud, Helène Delpech, Marta Jarlier, Martine Pugnière, Bruno Robert, Anthony Puel, Lucie Martin, Flavie Landomiel, Thomas Bourquard, Oussama Achour, Ingrid Fruitier-Arnaudin, Alexandre Pichard, Emmanuel Deshayes, Andrei Turtoi, Anne Poupon, Joëlle Simony-Lafontaine, Florence Boissière-Michot, Nelly Pirot, Florence Bernex, William Jacot, Stanislas du Manoir, Charles Theillet, Jean-Pierre Pouget, Isabelle Navarro-Teulon, Nathalie Bonnefoy, André Pèlegrin, Thierry Chardès, Pierre Martineau, Emmanuelle Liaudet-Coopman.

J Immunother Cancer, 2019

https://jitc.bmj.com/content/7/1/29.long

Construction of Synthetic Antibody Libraries.

Déborah Caucheteur, Gautier Robin, Vincent Parez, Pierre Martineau

Methods Mol Biol, 2018

https://link.springer.com/protocol/10.1007/978-1-4939-8648-4_5

Construction of a Synthetic Antibody Gene Library for the Selection of Intrabodies and Antibodies.

Déborah Caucheteur, Gautier Robin, Vincent Parez, Pierre Martineau

Methods Mol Biol., 2018

https://link.springer.com/protocol/10.1007/978-1-4939-7447-4_12

Restricted diversity of antigen binding residues of antibodies revealed by computational alanine scanning of 227 antibody-antigen complexes.

Gautier Robin, Yoshiteru Sato, Dominique Desplancq, Natacha Rochel, Etienne Weiss, Pierre Martineau.

J. Mol. Biol, 2014

https://www.sciencedirect.com/science/article/pii/S0022283614004562?via%3Dihub

Generation of an intrabody-based reagent suitable for imaging endogenous proliferating cell nuclear antigen in living cancer cells.

Guillaume Freund, Dominique Desplancq, Audrey Stoessel, Robin Weinsanto, Annie-Paule Sibler, Gautier Robin, Pierre Martineau, Pascal Didier, Jérôme Wagner, Etienne Weiss.

J Mol Recognit, 2014

https://onlinelibrary.wiley.com/doi/10.1002/jmr.2378

By-Passing Large Screening Experiments Using Sequencing as a Tool to Identify scFv Fragments Targeting Atherosclerotic Lesions in a Novel In Vivo Phage Display Selection.

Kamel Deramchia, Marie-Josee Jacobin-Valat,Jeanny Laroche-Traineau, Stephane Bonetto, Stephane Sanchez, Pierre Dos Santos, Philippe Massot, Jean-Michel Franconi, Pierre Martineau , Gisele Clofent-Sanchez

Int. J. Mol. Sci. 2012

https://www.mdpi.com/1422-0067/13/6/6902

Synthetic customized scFv libraries.

Gautier Robin, Pierre Martineau.

Methods Mol Biol. 2012

https://link.springer.com/protocol/10.1007/978-1-61779-974-7_6

Redirecting NK cells mediated tumor cell lysis by a new recombinant bifunctional protein.

Claire Germain, Emmanuelle Campigna, Imed Salhi, Sébastien Morisseau, Isabelle Navarro-Teulon, Jean-Pierre Mach, André Pèlegrin, Bruno Robert.

Protein Eng. Des. Sel. , 2008

https://pmc.ncbi.nlm.nih.gov/articles/PMC2759461/

A focused antibody library for selecting scFvs expressed at high levels in the cytoplasm.

Pascal Philibert, Audrey Stoessel, Wei Wang, Annie-Paule Sibler, Nicole Bec, Christian Larroque, Jeffery G Saven, Jérôme Courtête, Etienne Weiss , Pierre Martineau.

BMC Biotechnology, 2007.

https://bmcbiotechnol.biomedcentral.com/articles/10.1186/1472-6750-7-81

In vitro folding and thermodynamic stability of an antibody fragment selected in Vivo for high expression levels in Escherichia coli cytoplasm.

Pierre Martineau, Jean-Michel Betton.

J Mol Biol 292 (1999).

https://www.sciencedirect.com/science/article/abs/pii/S0022283699931054

Expression of an antibody fragment at high levels in the bacterial cytoplasm.

Pierre Martineau, Peter Jones, Greg Winter

J Mol Biol, 1998.

https://www.sciencedirect.com/science/article/abs/pii/S002228369891840X

Presentations and posters

Harnessing the Tumor Microenvironment: Converting hurdles into opportunities for innovative therapeutic antibodies.

Baptiste Gouyou, Lindsay Alcaraz, Margaux Maurel, Tristan Mangeat, Adrien Laroche, Johanna Marines, Bernard Pau, Anne Chevrel

Antibody Engineering & Therapeutics Europe 2025

Antibody Industrial Symposium 2025

 
First-in-class anti-TRPV6 antibody as a new therapeutic agent in cancer.

Lindsay B. Alcaraz, Vincent Roux-Portalez, Aurélien Haustrate, Gautier Robin, Alexia Parmentier, Clément Cordier, Florence Boissière-Michot, Amélie Gudin-de-Vallerin, Evelyne Lopez-Crapez, Gaelle Fromont-Hankard, Tristan Mangeat, Margaux Maurel, Marianne Le Gall, Thierry Chardès, Bruno Robert, Yoann Sottejeau, Diego Tosi, Natacha Prevarskaya, V’yacheslav Lehen’kyi, Bernard Pau, Johanna Marines

American Association for Cancer Research (AACR) 2025

Antibody Industrial Symposium 2025
 
Targeting tumor micro-environment with pH-sensitive human antibodies.

Anne Chevrel

12th Antibody Industrial Symposium, 2024

Development of pH-sensitive anti-HER2 antibodies to optimize therapeutic index.

Gautier Robin

Festival of Biologics Basel, 2023

pH-sensitive antibodies targeting HER2.

Gautier Robin, Tristan Mangeat.

10th Antibody Industrial Symposium, 2022

Rationally Engineered human antibody libraries and their use for the selection of therapeutic antibodies.

Gautier Robin

Antibody Engineering & Therapeutics USA, 2021